| Survival: | 7.6 months |
| Toxicity Grade: | 3 |
| Treatments: | Biologic therapy |
| Drugs: | |
| Country: | Netherlands |
| City/State/Province: | Amsterdam |
| Hospital: | Netherlands Cancer Institute |
| Journal: | Link |
| Date: | 5/2005 |
| Description: |
| Patients: This Phase II study involved 40 patients with malignant pleural mesothelioma. Thirty-four patients were men, and six were women. The median age was 62 years. All but one patient was exposed to asbestos. Twenty-five patients had stage 3 or 4 disease. Twenty patients had received prior chemotherapy, radiotherapy, or surgery. Treatment: The treatment consisted of one biologic agent: thalidomide. Thalidomide is thought to be an anti-angiogenesis agent that helps stop new blood vessels from forming. Toxicities: Grade 2-3 toxicities included an allergic reaction, neurotoxicity, and constipation. Results: The median survival was 7.6 months (230 days). Correspondence: Paul Baas, MD |